ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Treatment outcomes of multidrug-resistant tuberculosis patients receiving ambulatory treatment in Shenzhen, China: a retrospective cohort study

Lecai, Ji; Mijiti, Peierdun; Chuangyue, Hong; Qian, Gao*; Weiguo, Tan; Jihong, Chen*复旦大学; 南方医科大学
Frontiers in Public Health2023-6-20DOI: 10.3389/fpubh.2023.1134938
3被引21阅读
引用收藏
分享

摘要

Background: WHO recommended multidrug-resistant tuberculosis (MDR-TB) should be treated mainly under ambulatory model, but outcome of ambulatory treatment of MDR-TB in China was little known. @@@ Methods: The clinical data of 261 MDR-TB patients treated as outpatients in Shenzhen, China during 2010-2015 were collected and analyzed retrospectively. @@@ Results: Of 261 MDR-TB patients receiving ambulatory treatment, 71.1% (186/261) achieved treatment success (cured or completed treatment), 0.4% (1/261) died during treatment, 11.5% (30/261) had treatment failure or relapse, 8.0% (21/261) were lost to follow-up, and 8.8% (23/261) were transferred out. The culture conversion rate at 6 months was 85.0%. Although 91.6% (239/261) of patients experienced at least one adverse event (AE), only 2% of AEs caused permanent discontinuation of one or more drugs. Multivariate analysis showed that previous TB treatment, regimens containing capreomycin and resistance to FQs were associated with poor outcomes, while experiencing three or more AEs was associated with good outcomes. @@@ Conclusion: Good treatment success rates and early culture conversions were achieved with entirely ambulatory treatment of MDR-TB patients in Shenzhen, supporting WHO recommendations. Advantageous aspects of the local TB control program, including accessible and affordable second-line drugs, patient support, active monitoring and proper management of AEs and well-implemented DOT likely contributed to treatment success rates.

学科与关键词

关键词
MDR-TBambulatory treatmenttreatment outcomesDOTMDR/RR-TB
相关
加载中…
  • Predictors and Trends of MDR/RR-TB in Shenzhen China: A Retrospective 2012-2020 Period Analysis
    Ji Lecai; Mijiti, Peierdun; Hong Chuangyue; Li Mingzhen; Gao Qian*; Tan Weiguo; Chen Jihong*Infection and Drug Resistance, 2021, 14: 4481-4491.被引 7
  • Spatial analysis of tuberculosis treatment outcomes in Shanghai: implications for tuberculosis control
    Zhang, Jing; Shen, Xin; Yang, Chongguang; Chen, Yue; Guo, Juntao; Wang, Decheng; Zhang, Jun; Lynn, Henry; Hu, Yi; Pan, Qichao; Zhang, Zhijie*Epidemiology and Health, 2022, 44: e2022045.
  • A Review of Clinical Pharmacokinetic and Pharmacodynamic Relationships and Clinical Implications for Drugs Used to Treat Multi-drug Resistant Tuberculosis
    Wilby, Kyle John*; Hussain, Farhat NazEUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2020, 45(3): 305-313.被引 5
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Public Health
发表日期
2023-06-20
卷期
第 11 卷
页码
1134938
DOI
10.3389/fpubh.2023.1134938
成果收录
SSCI
资助标注
Sanming project of Medicine in Shenzhen [SZSM201611030]; Guangdong Medical Science and Technology Research Fund [B2021075]

作者

  • L

    Lecai, Ji (第一作者)

    2 · southern med univ

  • M

    Mijiti, Peierdun

    xinjiang med univ

查看全部 6 位作者收起作者
  • C

    Chuangyue, Hong

  • Q

    Qian, Gao (通讯)

    fudan univ

  • W

    Weiguo, Tan

  • J

    Jihong, Chen (通讯)

    2 · shenzhen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417